Skip to Content
Merck
All Photos(3)

Key Documents

HCYTMAG-60K-PX41

Millipore

MILLIPLEX® Human Cytokine/Chemokine Magnetic Bead Panel - Premixed 41 Plex - Immunology Multiplex Assay

Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.

Synonym(s):

Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 87-107%
standard curve range: 3.2-10,000 pg/mL

technique(s)

multiplexing: suitable

compatibility

configured for Premixed

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

General description

“Cytokine” is a general term used for a diverse group of soluble proteins and peptides which act as regulators under both normal and pathological conditions to modulate the functional activities of individual cells and tissues. These proteins also mediate direct interactions between cells and regulate processes taking place in the extracellular environment. Cytokines differ from hormones in that they act on a wider spectrum of target cells. Also, unlike hormones, they are not produced by specialized cells which are organized in specialized glands. The cytokine group of proteins includes lymphokines, interferons, colony stimulating factors and chemokines. Cytokine and chemokine research plays a significant role in achieving a deeper understanding of the immune system and its multi-faceted response to most antigens, as well as disease states such as inflammatory disease, allergic reactions, irritable bowel disease (IBD), sepsis, and cancer.

The MILLIPLEX® Human Cytokine / Chemokine Panel 1 enables you to focus on the therapeutic potential of cytokines as well as the modulation of cytokine expression.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cytokines/Chemokines

Specificity

Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Application

  • Analytes: sCD40L, EGF, Eotaxin/CCL11, FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, TGF-α, TNF-α, TNF-β, VEGF
  • Recommended Sample type: Serum, plasma, or tissue/cell lysate and culture supernatant samples
  • Recommended Sample dilution: Neat plasma or serum. Tissue culture supernatant may require a dilution with an appropriate control medium prior to assay. RANTES, PDGF-AA and PDGF-AB/BB require a 1:100 dilution of plasma/serum samples.
  • NOTE: RANTES, PDGF-AA and PDGF-AB/BB cannot be plexed with other cytokines in this panel due to a required 1:100 dilution of plasma/serum samples.
  • Assay Run Time: Overnight or two-hour primary incubation. For best results, an overnight incubation is recommended
  • Research Category: Inflammation & Immunology
  • Research Subcategory: Obesity, Metabolic Disorders, Inflammation & Autoimmune Mechanisms

Packaging

96 well plate

Storage and Stability

Recommended storage for kit components is 2 - 8°C.

Other Notes

Note: RANTES, PDGF-AA and PDGF-AB/AA cannot be plexed with other analytes for serum/plasma.
Sensitivity: Refer to kit protocol for sensitivities for individual cytokines/chemokines.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Target Organs

Respiratory Tract

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Anastasiia S Boiko et al.
Pharmaceuticals (Basel, Switzerland), 14(5) (2021-06-03)
The present study aims at comparing the change in cytokine levels in schizophrenia patients treated with atypical antipsychotics, with or without metabolic syndrome (MetS). The study included 101 patients with schizophrenia, 38 with and 63 without MetS, who received risperidone
Patrick W Underwood et al.
Cancers, 12(2) (2020-02-07)
Smoking is highly associated with pancreatic cancer. Nicotine, the addictive component of tobacco, is involved in pancreatic cancer tumorigenesis, metastasis, and chemoresistance. This work aimed to describe the role of nicotine within the pancreatic cancer tumor microenvironment. Nicotine treatment was
Patrick W Underwood et al.
Journal of the American College of Surgeons, 230(1), 26-36 (2019-11-02)
Endoscopic ultrasound-guided fine-needle aspiration fails to diagnose up to 25% of patients with pancreatic ductal adenocarcinoma (PDAC). Proteomics can help to overcome this clinical dilemma. We hypothesized that soluble protein signatures can differentiate PDAC from benign tissues. Tissues were obtained
Vage Markosyan et al.
International journal of molecular sciences, 21(18) (2020-09-24)
Currently, the main fundamental and clinical interest for stroke therapy is focused on developing a neuroprotective treatment of a penumbra region within the therapeutic window. The development of treatments for ischemic stroke in at-risk patients is of particular interest. Preventive
Lauren Anton et al.
Frontiers in microbiology, 9, 2181-2181 (2018-10-24)
Cervicovaginal (CV) microbiota is associated with vaginal health and disease in non-pregnant women. Recent studies in pregnant women suggest that specific CV microbes are associated with preterm birth (PTB). While the associations between CV microbiota and adverse outcomes have been

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service